by Paul McIntosh | Jun 1, 2021 | 2021, Press Releases
Peer reviewed journal article highlights Company’s novel antifungal peptide’s activity against a broad range of fungal pathogens with no off target cytotoxicity Aberdeen, June 1, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune...
by Paul McIntosh | May 21, 2021 | 2021, Events
NovaBiotics are looking forward to participating at the upcoming BIO Digital Meeting taking place on June 10-11 & 14-18, 2021. The team are ready to meet with all interested parties and explain how we are using immunology to deliver novel therapies for...
by Paul McIntosh | Mar 30, 2021 | 2021, Blog Post
By Grant Ellis, Director, NovaBiotics Ltd A number of commentators are now saying that as a result of the vaccines, COVID 19 will be akin to flu – something that comes around every year but for most of us nothing more than an inconvenience and only severely...
by Paul McIntosh | Feb 26, 2021 | 2021, Press Releases
Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...
by Paul McIntosh | Feb 2, 2021 | 2021, Events
CEO Dr Deborah O’Neil and the NovaBiotics team will be attending the BIO CEO & Investor Conference, hosted by the Biotechnology Innovation Organization on the 16th-18th February 2021. Meet with us through the event portal BIO CEO & Investor Event to...
Recent Comments